Alzamend Neuro, Inc. Common Stock
Veridion Score
Composite trend over time
Why is ALZN moving today?
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ALZN.
ALZN insider activity
Alzamend Neuro, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $2.1M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | 2026-04-14 | AULT MILTON C III | Insider | buy | $1.00 | 108,388 | 116,648 | $109K | SEC Form 4 |
| 2025-12-30 | 2025-12-23 | AULT MILTON C III | Insider | sell | $2.07 | 1,851 | Not reported | $4K | SEC Form 4 |
| 2025-12-23 | 2025-12-19 | Horne William B. | Insider | sell | $2.12 | 3,333 | Not reported | $7K | SEC Form 4 |
| 2025-10-24 | 2025-10-23 | McGrath Lynne Fahey | Insider | sell | $2.29 | 30 | 25 | $69 | SEC Form 4 |
| 2025-10-10 | 2025-10-09 | AULT MILTON C III | Insider | sell | $2.32 | 20,397 | 8,260 | $47K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 39 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moALZN contract awards, year to date.
Public federal awards linked to this ticker.
ALZN lobbying filings, year to date.
Registered lobbying filings matched to Alzamend Neuro, Inc. Common Stock.